Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucinactant for inhalation versus nCPAP alone in preterm neonates with respiratory distress syndrome
2018-000106-32Phase 2Terminated
- Sponsor
- Windtree Therapeutics, Inc.
- Start
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of lucinactant in respiratory distress syndrome (RDS) (2 arms), sponsored by Windtree Therapeutics, Inc. Primary endpoint: Respiratory failure due to RDS or death within the first 28 days of life. Started Mar 2019; status: terminated.
02
Drugs
lucinactant
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on 2018-000106-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000106-32.